Office for Technology Commercialization

Improved Impedance Measurements for Pulmonary Edema from Pacemaker or CRT-ICD Leads

Technology #z08220

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Change in Impedance Caused by Pulmonary EdemaPacemaker Leads Pick Up BioimpedancePulmonary Edema in Heart Failure Patient
Robert P Patterson, PhD
Emeritus Professor, Department of Physical Medicine and Rehabilitation
External Link (
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection
US Patent 8,731,653


US Patent Pending

Improved Monitoring of Heart Failure Using Bioimpedance

Bioimpedance and Pulmonary Edema in Heart Failure Patients

One of the major problems facing patients with heart failure is pulmonary edema. It is now possible to monitor the extent of pulmonary edema by measuring impedance from the leads of a cardiac pacemaker, a cardiac resynchronization therapy device (CRT-D) or an implantable cardioverter defibrillator (ICD). By taking advantage of the body's natural electrophysiology, decreases in the impedance between the leads and devices indicate increases in fluid buildup in the lungs. By calibrating this impedance, doctors can receive real-time information about the level of pulmonary edema in a patient, thus alerting them to worsening heart failure.

MN-IP Try and Buy
  • Trial period of 6 to 12 months. $5000/6 months.
  • Fee waived if MN operating company or if sponsoring $50,000+ in research.
  • Exclusive license for a $25,000 conversion payment.
  • No patent expenses.
  • 1.5% royalty after $1 million in product sales. 1.0% for MN companies.

** View the Term Sheet *
This technology is also offered as a portfolio with z04067 and z05107. View the portfolio Term Sheet *

** Contact Kevin Anderson for specific details. **

Improving Impedance Measurements from Cardiac Pacemaker Leads

There are currently several technologies that measure this impedance, but researchers at the University of Minnesota have developed a method to increase the sensitivity of measuring impedance by three to four times. This improvement involves adding two voltage pick up electrodes along the leads running to the superior vena cava and right ventricle. This is convenient because the invention takes advantage of the leads which are placed in an optimal location to measure pulmonary edema with high sensitivity. Because the electrodes can be placed along a single lead in the right ventricle, bioimpedance measurement capabilities can be coupled with a wider variety of devices, not just CRT-D or ICD pacing systems.


  • Increases sensitivity of measuring bioimpedance three to four times
  • Measuring impedance allows doctors to assess the extent of pulmonary edema from preplaced pacemaker, CRT-D or ICD leads in heart failure patients
  • Alerts physician to worsening heart failure

Phase of Development Results have been obtained from a detailed electrical model of the thorax used for several other patents.